RMTG (Regenerative Medical Technology Group) Quick Ratio: 0.03 (As of Mar. 2026)— 40% Below Median
What is Regenerative Medical Technology Group Quick Ratio?
Regenerative Medical Technology GroupRMTG Quick Ratio is 0.03 as of Mar. 2026, which is 40% below its 10-year median of 0.05. The stock has 4 warning signs investors should review. Among 1,413 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 98.66% on this metric.
Regenerative Medical Technology Group has a quick ratio of 0.03. It indicates that the company cannot currently fully pay back its current liabilities.
RMTG's Quick Ratio is ranked worse than 98.66% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs RMTG: 0.03
Regenerative Medical Technology Group (OTCPK:RMTG) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Regenerative Medical Technology Group Quick Ratio Related Terms
Regenerative Medical Technology Group Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group Quick Ratio Chart
For the Biotechnology subindustry, Regenerative Medical Technology Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group Quick Ratio vs Biotechnology Industry
Regenerative Medical Technology Group Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a Quick Ratio of 0.03 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Regenerative Medical Technology Group and its competitors. This is 40% below median its historical median of 0.05. Over the past decade, Regenerative Medical Technology Group's Quick Ratio has ranged from 0.01 to 9.39. According to the industry distribution chart, Regenerative Medical Technology Group ranks #1394 out of 1413 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Regenerative Medical Technology Group's Quick Ratio too high?
Regenerative Medical Technology Group's current Quick Ratio of 0.03 is 40% below median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 9.39. The Biotechnology industry median Quick Ratio is 3.60. Regenerative Medical Technology Group's value of 0.03 is 99.2% below this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #1394 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regenerative Medical Technology Group's Quick Ratio compare to PTIX and CERO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #1394 out of 1413 companies for Quick Ratio. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median Quick Ratio is 3.60. Regenerative Medical Technology Group's value of 0.03 is 99.2% below this benchmark. Historically, Regenerative Medical Technology Group's own Quick Ratio has ranged from 0.01 to 9.39 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 3.60, Regenerative Medical Technology Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current Quick Ratio of 0.03 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Regenerative Medical Technology Group and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current Quick Ratio is 0.03, which is 40% below median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.06, compared to a current price of $0.05 — trading 24.7% below its estimated fair value. The current Quick Ratio is 0.03, which is 40% below median its 10-year median of 0.05 and 99.2% below the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Quick Ratio is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 